More Videos
- Sam Waksal: "Moving On Up" To The East Side
- Another "Short" Story About Pfizer & Dendreon
- Predictions: 9 For '09 In Pharma
- Johnson & Johnson Is Latest FDA Casualty
- Genentech: Roche Says One Thing, Investors Say Another
- Schering-Plough: The Reviews Are In
- Pharma Updates And What You Need To Know
- The Emails Fly On GM, Ford CEO's Corporate Jets
- Merck Offering To Help Patients—Or Itself?
- GM, Ford & Chrysler CEOs Take Their Medicine
- Stock Pickers Like a Builder and a Biotech Firm
- BofA and Merrill Job Cuts Could Now Reach 30,000
- Small Players Vie for ‘Green Car’ Loans
- Bailout Monitor Sees Lack of a Coherent Plan
- Pros: Searching the Gloom ... Bright Spot in Japan
- Putting a Value on a C.E.O.
- Where the Layoffs Are—Is Your Firm on the List?
- Treasurys Mostly Higher Despite Stock Gains
- BofA to Cut 10,000 Investment Banking Jobs
Text Size 
 |
CNBC.com |
] and, perhaps, some men and women are celebrating the tenth birthday of Viagra. So, happy birthday little blue pill. But I don't think the folks at Pfizer are popping the champagne corks. Today our stock whiz, Robert Hum, informs me that PFE closed at its lowest level since before the Food and Drug Administration approved Viagra.
The previous nearest closing low occured on October 1st, 1997. Since the world's biggest drug company held its analyst meeting earlier this month, the shares have fallen from $22-and-change to $20-and-change. As Jim Cramer pointed out this morning, though, the high dividend yield might make the stock attractive at this level.
Part of the problem is Pfizer's drug development pipeline. For example, it will not be a headliner at the American College of Cardiology meeting where I'm off to tomorrow. And this year's ACC is not all about Merck [MRK
Loading...
()
] and Schering-Plough's [SGP
Loading...
()
] Vytorin.
Tomorrow Lilly [LLY
Loading...
()
] releases data on whether its bloodthinner, which is on a fast track for possible FDA approval, did a better job than Plavix (Bristol-Myers Squibb and Sanofi-Aventis) at preventing blood clots from forming in stent patients. And then on Monday morning, look for results coming out Monday morning on a weightloss and cholesterol drug from Merck.
See you bright and early on "Squawk Box" at 6 a.m. ET live from McCormick Place.
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes